Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 341 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Combination pill Clear all
Recruiting Phase 1 Interventional

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

NCT05210374
View directory record Official record
Conditions
Relapsed Sarcomas
Interventions
Disulfiram, Copper Gluconate, Liposomal Doxorubicin (Doxil)
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 31, 2026, 7:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Melatonin-Micronutrients for Osteopenia Treatment Study

NCT01870115
View directory record Official record
Conditions
Osteoporosis, Osteopenia
Interventions
Fiber Pill, Melatonin, Strontium citrate, Vitamins D3 and K2
Dietary Supplement
Lead sponsor
Duquesne University
Other
Eligibility
Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 31, 2026, 7:42 PM EDT
Completed Phase 3 Interventional

Combined Pharmacotherapies for Alcoholism

NCT00768508
View directory record Official record
Conditions
Alcoholism
Interventions
Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy, Naltrexone 50 mg/day + Cognitive Behavioral Therapy, Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy, Placebo + Cognitive Behavioral Therapy
Drug · Other
Lead sponsor
Bankole Johnson
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 31, 2026, 7:42 PM EDT
Recruiting Phase 2 Interventional

The COSMYC Trial (COmbined Suppression of MYC)

NCT06922318
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Weekly Dosing of Malarone ® for Prevention of Malaria

NCT00984256
View directory record Official record
Conditions
Malaria
Interventions
Atovaquone Proguanil, Procedure - malaria challenge
Drug · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 31, 2026, 7:42 PM EDT
Not listed Phase 4 Interventional

Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair

NCT04573504
View directory record Official record
Conditions
Vaginal Laceration During Delivery
Interventions
Augmentin/Flagyl or Augmentin/Clindamycin, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 31, 2026, 7:42 PM EDT
Completed Not applicable Interventional Results available

Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo

NCT02317744
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Naltrexone and bupropion combination, Pill Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 31, 2026, 7:42 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.

NCT00386607
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Valsartan, Hydrochlorothiazide (HCTZ)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 31, 2026, 7:42 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With Obesity

NCT06242535
View directory record Official record
Conditions
Insulin Resistance, Obesity, Cardiovascular Diseases, Cognitive Impairment, Physical Disability, Depression, Inflammation, Hormone Deficiency, Physical Inactivity, Hyperlipidemias, Hypertension, Overeating
Interventions
GLY-LOW
Biological
Lead sponsor
Hoskinson Health and Wellness Clinic
Industry
Eligibility
56 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Gillette, Wyoming
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 31, 2026, 7:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Assessment of DHA On Reducing Early Preterm Birth

NCT02626299
View directory record Official record
Conditions
Preterm Birth
Interventions
Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 31, 2026, 7:42 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Influences of Long-acting Reversible Contraceptives on Iron Status and Physiological Responses to Extreme Environments in Women

NCT06909695
View directory record Official record
Conditions
Contraception, Iron Deficiencies
Interventions
Blood volume and environmental testing
Other
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 31, 2026, 7:42 PM EDT
Withdrawn Phase 2 Interventional

Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis

NCT01141296
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
fenofibrate, placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
21 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Miami, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 31, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses

NCT04140292
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Photodynamic therapy (PDT), Vitamin D3
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2022 · Synced Oct 31, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Oral Warts in HIV+ Patients

NCT00454181
View directory record Official record
Conditions
Papillomatosis, HIV Infections
Interventions
Interferon-alpha, placebo
Drug · Other
Lead sponsor
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
San Francisco, California • Fort Lauderdale, Florida • Augusta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 31, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Combining Armodafinil With Neuro-rehabilitation to Improve Neurological Recovery and Reduce Disability Post-Stroke

NCT01896128
View directory record Official record
Conditions
Stroke, Cerebrovascular Accident, Hemiparesis
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Burke Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 31, 2026, 7:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Maintenance Treatment for Abstinent Smokers

NCT00063323
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 75 Years
Enrollment
589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 31, 2026, 7:42 PM EDT
Completed Phase 4 Interventional Results available

The ISLAND Study: InSuLa Assessed Needs for Depression

NCT02137369
View directory record Official record
Conditions
Depression
Interventions
Selective serotonin re-uptake inhibitor, Cognitive Behavioral Therapy, Combination treatment (SSRI + CBT)
Drug · Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 31, 2026, 7:42 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Cerebrovascular and Cognitive Improvement by Resveratrol (resVida) and Fruitflow-II (CCIRF-II)

NCT01766180
View directory record Official record
Conditions
Memory Impairment
Interventions
Fruitflow-II, resVida
Drug
Lead sponsor
Neurolgy Institute for Brain Health and Fitness
Other
Eligibility
50 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Oct 31, 2026, 7:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

NCT00765674
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Oct 31, 2026, 7:42 PM EDT
Withdrawn Phase 2 Interventional

Use of Zolpidem in Parkinson's Disease

NCT01351168
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Levodopa, Zolpidem first dose, Zolpidem second dose, sugar pill
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
30 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 31, 2026, 7:42 PM EDT
Completed Phase 1 Interventional

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

NCT03524326
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma
Interventions
Lenvatinib Pill, Cetuximab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 31, 2026, 7:42 PM EDT
Withdrawn Phase 1 Interventional

Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain

NCT01269671
View directory record Official record
Conditions
Functional Abdominal Pain, Irritable Bowel Syndrome, Functional Dyspepsia
Interventions
Melatonin, Peppermint Oil (mentharil), and Simethicone, Sugar pill
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 31, 2026, 7:42 PM EDT
Completed Phase 1 Interventional

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
View directory record Official record
Conditions
Hypertension
Interventions
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
Drug · Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 31, 2026, 7:42 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

NCT03539900
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 31, 2026, 7:42 PM EDT